Lando & Anastasi, LLP
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
Novartis AG The Trustees of the University of Pennsylvania
A A A C A A A A A C C A C C A C C A
A61K A61K A61K C07K A61K A61K A61P A61K A61P C07K C07K A61K C07K C07K A61P C07K C07K A61K
inventional additional additional inventional additional additional inventional inventional inventional additional inventional inventional inventional inventional inventional additional additional inventional
Li Andreas Steven Ju Young Hans Marco Na Ming Lu Jennifer Barbara Jennifer Mary Elena Thai Carl H. Naveen Kumar Jimin Saar
Zhou Loew Highfill Kim Bitter Ruella Li Lei Huang Brogdon Brannetti Bordeaux Orlando Tran June Dakappagari Zhang Gill